國家衛生研究院 NHRI:Item 3990099045/2998

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Periodical Articles > Item 3990099045/2998

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2998

Title:	Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy
Authors:	Chen, YM;Perng, RP;Yang, KY;Lin, WC;Wu, HW;Tsai, CM;Whang-Peng, J
Contributors:	National Institute of Cancer Research
Abstract:	We conducted a phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy in patients with Iron-small cell lung cancer (NSCLC) who had failed previous chemotherapy, in order to assess the response and toxicity of TIEP. Between November 1997 and May 1999, 25 patients were treated. Twelve of the 25 patients (48%) had been previously treated with cisplatin-based combination chemotherapy. TIEP doses were tamoxifen 60 mg oral twice daily on days 1-3; ifosfamide 2.4 g/m(2) intravenous infusion (IV) 60 min with mesna on day 2; epirubicin 40 mg/m(2) IV bolus on day 2: and cisplatin 50 mg/m2 IV 60 min on day 2 every 4 weeks for up to six cycles. Seventy one cycles were given to 25 patients, with a median of three cycles (range one to six cycles). All patients were evaluable for toxicity profile and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 neutropenia occurred in 15 patients (60%) during treatment, as well as in 31% of the total courses. Febrile neutropenia occurred in two patients. No toxic death occurred in this study. Grade 3 thrombocytopenia occurred in five patients with five cycles. Toxicities other than myelosuppression were few and mild in severity. After two cycles of treatment. five of 25 patients (20%) had a partial response (95% confidence interval 4.3-35.7%), Among 12 patients previously treated with cisplatin-based chemotherapy, three patients (25%) achieved a partial response. The median time to disease progression was 4.9 months and median survival was 7.7 months. The response rate and median survival were better than in our previous study of salvage chemotherapy with ifosfamide. 5-FU, and leucovorin; and with ifosfamide, epirubicin. 5-FU, and leucovorin. In conclusion, TIEP appears to be an active combination regimen with an acceptable toxicity profile in Chinese patients with NSCLC who have failed previous chemotherapy.
Keywords:	Oncology;Respiratory System
Date:	2000-08
Relation:	Lung Cancer. 2000 Aug;29(2):139-146.
Link to:	http://dx.doi.org/10.1016/S0169-5002(00)00106-9
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0169-5002&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000088815800005
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033837675
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Periodical Articles

Files in This Item:

File	Description	Size	Format
000088815800005.pdf		84Kb	Adobe PDF	770	View/Open

Loading...